InsidersTradesSigma
Track the Beta Bionics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €900.2m. The latest transaction was reported on 30 June 2026 (Levée d'options). Among the most active insiders: Feider Stephen. Every trade is openly available.
91
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€2m
40 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Beta Bionics, Inc. Buy (bullish), based on 11 analysts. Average price target: US$20.31.
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,422 of 28,901 companies
24.0
score / 100
Value19
Quality29
FCF yld-6.3%
Earn yld-8.2%
EV/EBITDA·
ROE-26%
Gross mgn55%
Net mgn-73%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 June 2026
Declarations91 total
4,982 sharesCommon StockSEC:0002048588-26-000009:0
5,104 sharesCommon StockSEC:0002048588-26-000009:1
4,896 sharesCommon StockSEC:0002048588-26-000009:2
4,896 sharesCommon StockSEC:0002048588-26-000009:3
4,896 shares@ US$17.03040.012% mcap48.8% of flowCommonSEC144:0001628280-26-045940
5,104 shares@ US$17.04680.012% mcap51.2% of flowCommonSEC144:0001628280-26-045803
1,406 sharesCommon StockSEC:0002048467-26-000005:0
1,258 sharesCommon StockSEC:0002048497-26-000009:0
1,258 shares@ US$14.96570.0026% mcap100.0% of flowCommonSEC144:0001628280-26-045235
1,406 shares@ US$13.670.0027% mcap100.0% of flowCommonSEC144:0001950047-26-006469
275 shares@ US$12.310.0004% mcap4.8% of flowCommon StockSEC:0002048497-26-000008:0
2,811 shares@ US$14.000.0048% mcap66.5% of flowCommon StockSEC:0002048467-26-000004:0
275 shares@ US$12.310.0004% mcap3.7% of flowCommonSEC144:0001628280-26-040713
5,329 shares@ US$12.790.0088% mcap75.0% of flowCommon StockSEC144:0002048497-26-000006
4,378 shares@ US$12.790.0073% mcap100.0% of flowCommon StockSEC144:0002048500-26-000008
6,676 shares@ US$12.790.011% mcap32.9% of flowCommon StockSEC144:0002048588-26-000007
16,872 shares@ US$12.790.028% mcap100.0% of flowCommon StockSEC144:0002048593-26-000005
4,222 shares@ US$12.790.0070% mcap100.0% of flowCommon StockSEC144:0002051384-26-000005
5,329 shares@ US$12.6071100.0% of flowCommon StockSEC:0002048497-26-000007:0
4,378 shares@ US$12.6071100.0% of flowCommon StockSEC:0002048500-26-000009:0
6,676 shares@ US$12.607114.8% of flowCommon StockSEC:0002048588-26-000008:0
16,872 shares@ US$12.6071100.0% of flowCommon StockSEC:0002048593-26-000006:0
4,222 shares@ US$12.6071100.0% of flowCommon StockSEC:0002051384-26-000006:0
1,000 shares@ US$9.9547.1% of flowCommon StockSEC:0002048466-26-000003:0
998 shares@ US$11.2152.9% of flowComon StockSEC:0002048466-26-000003:2
25 of 91 declarations
Acerca de Beta Bionics, Inc.
Beta Bionics, Inc. es una empresa centrada en el desarrollo de tecnologías médicas para el tratamiento de la diabetes. Su objetivo es crear dispositivos innovadores para mejorar el manejo de la enfermedad.